LadRx (NASDAQ:CYTR) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

LadRx Stock Performance

The company’s 50-day moving average price is $0.10. LadRx has a one year low of $0.05 and a one year high of $0.86.

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.